About Us

Gradient is developing a novel trans-vascular, catheter based technology based on proven clinical, human data to treat pulmonary hypertension, a fatal condition that effects approximately 500,000 patients per year worldwide. This disruptive therapy results in a reduction in pulmonary vascular resistance and improvement in cardiovascular hemodynamics, symptoms, and costs of care, and has shown breakthrough potential as a life-saving treatment.